Ranolazine in symptomatic diabetic patients without obstructive coronary artery disease: Impact on microvascular and diastolic function

Journal of the American Heart Association

Volumn 6, Issue 5, 2017, Pages

  Shah, Nishant R ^a,b   Cheezum, Michael K ^a   Veeranna, Vikas ^a   Horgan, Stephen J ^a   Taqueti, Viviany R ^a   Murthy, Venkatesh L ^c   Foster, Courtney ^a   Hainer, Jon ^a   Daniels, Karla M ^a   Rivero, Jose ^a   Shah, Amil M ^a   Stone, Peter H ^a   Morrow, David A ^a   Steigner, Michael L ^a   Dorbala, Sharmila ^a   Blankstein, Ron ^a   Di Carli, Marcelo F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Diabetes mellitus; Microvascular dysfunction; Positron emission tomography; Randomized controlled trial; Ranolazine

Indexed keywords

ACETYLSALICYLIC ACID; AMMONIA; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LONG ACTING DRUG; NITRIC ACID DERIVATIVE; NITROGEN 13; PLACEBO; RANOLAZINE; CARDIOVASCULAR AGENT;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BICYCLE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY FLOW RESERVE; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC DYSFUNCTION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HALF LIFE; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART MUSCLE BLOOD FLOW; HEMATURIA; HUMAN; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; KIDNEY DISEASE; MALE; MICROANGIOPATHY; MONOTHERAPY; NAUSEA; NEPHROLITHIASIS; PATIENT COMPLIANCE; PET SCANNER; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REST; SUPINE POSITION; SYMPTOM; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; CONVALESCENCE; CORONARY ARTERY BLOOD FLOW; DIAGNOSTIC IMAGING; DIASTOLE; DRUG EFFECTS; EXERCISE TOLERANCE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; MASSACHUSETTS; MICROCIRCULATION; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME;

AGED; BOSTON; CARDIOVASCULAR AGENTS; CORONARY CIRCULATION; CROSS-OVER STUDIES; DIABETES MELLITUS; DIASTOLE; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; RANOLAZINE; RECOVERY OF FUNCTION; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 85019397115     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.116.005027     Document Type: Article

References (39)

1. Ong P, Athanasiadis A, Borgulya G, Mahrholdt H, Kaski JC, Sechtem U. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (abnormal coronary vasomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol. 2012;59: 655-662.
2. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, Olson M, Johnson BD, Mankad S, Sharaf BL, Rogers WJ, Wessel TR, Arant CB, Pohost GM, Lerman A, Quyyumi AA, Sopko G; Investigators W. Insights from the NHLBIsponsored women's ischemia syndrome evaluation (WISE) study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and genderoptimized diagnostic strategies. J Am Coll Cardiol. 2006;47:S4-S20.
3. Jespersen L, Hvelplund A, Abildstrom SZ, Pedersen F, Galatius S, Madsen JK, Jorgensen E, Kelbaek H, Prescott E. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of Major Adverse Cardiovascular Events. Eur Heart J. 2012;33:734-744.
4. Jespersen L, Abildstrom SZ, Hvelplund A, Galatius S, Madsen JK, Pedersen F, Hojberg S, Prescott E. Symptoms of angina pectoris increase the probability of disability pension and premature exit from the workforce even in the absence of obstructive coronary artery disease. Eur Heart J. 2013;34:3294-3303.
5. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-271.
6. Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, Dorbala S, Blankstein R, Di Carli MF. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation. 2012;126:1858-1868.
7. Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Dorbala S, Charytan DM, Blankstein R, Di Carli MF. Coronary vascular dysfunction and prognosis in patients with chronic kidney disease. JACC Cardiovasc Imaging. 2012;5:1025-1034.
8. Shah NR, Charytan DM, Murthy VL, Skali Lami H, Veeranna V, Cheezum MK, Taqueti VR, Kato T, Foster CR, Hainer J, Gaber M, Klein J, Dorbala S, Blankstein R, Di Carli MF. Prognostic value of coronary flow reserve in patients with dialysis-dependent ESRD. J Am Soc Nephrol. 2016;27:1823-1829.
9. Di Carli MF, Bianco-Batlles D, Landa ME, Kazmers A, Groehn H, Muzik O, Grunberger G. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation. 1999;100:813-819.
10. Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol. 2004;11:171-185.
11. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006;27:42-48.
12. Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, Ben-Yehuda O, Katz A, Jones PG, Olmsted A, Belardinelli L, Chaitman BR. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina). J Am Coll Cardiol. 2013;61:2038-2045.
13. Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther. 2006;318:214-222.
14. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92(suppl 4):iv6-iv14.
15. Stone PH, Chaitman BR, Stocke K, Sano J, DeVault A, Koch GG. The antiischemic mechanism of action of ranolazine in stable ischemic heart disease. J Am Coll Cardiol. 2010;56:934-942.
16. Mehta PK, Goykhman P, Thomson LE, Shufelt C, Wei J, Yang Y, Gill E, Minissian M, Shaw LJ, Slomka PJ, Slivka M, Berman DS, Bairey Merz CN. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging. 2011;4:514-522.
17. Tagliamonte E, Rigo F, Cirillo T, Astarita C, Quaranta G, Marinelli U, Caruso A, Romano C, Capuano N. Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease. Echocardiography. 2015;32:516-521.
18. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E. Effects of ranolazine on recurrent cardiovascular events in patients with non-STelevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775-1783.
19. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina) trial. J Am Coll Cardiol. 2006;48:566-575.
20. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, Fihn SD. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25:333-341.
21. Rose GA, Blackburn H. Cardiovascular survey methods. Monogr Ser World Health Organ. 1968;56:1-188.
22. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff AA; Investigators M. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375-1382.
23. Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, Blankstein R, Dorbala S, Sitek A, Pencina MJ, Di Carli MF. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation. 2011;124:2215-2224.
24. El Fakhri G, Kardan A, Sitek A, Dorbala S, Abi-Hatem N, Lahoud Y, Fischman A, Coughlan M, Yasuda T, Di Carli MF. Reproducibility and accuracy of quantitative myocardial blood flow assessment with (82)Rb PET: comparison with (13)N-ammonia PET. J Nucl Med. 2009;50:1062-1071.
25. Di Carli M, Czernin J, Hoh CK, Gerbaudo VH, Brunken RC, Huang SC, Phelps ME, Schelbert HR. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation. 1995;91:1944-1951.
26. Picard MH, Adams D, Bierig SM, Dent JM, Douglas PS, Gillam LD, Keller AM, Malenka DJ, Masoudi FA, McCulloch M, Pellikka PA, Peters PJ, Stainback RF, Strachan GM, Zoghbi WA; American Society of E. American Society of Echocardiography recommendations for quality echocardiography laboratory operations. J Am Soc Echocardiogr. 2011;24:1-10.
27. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing G, American Society of Echocardiography's G, Standards C, European Association of E. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
28. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107-133.
29. Villano A, Di Franco A, Nerla R, Sestito A, Tarzia P, Lamendola P, Di Monaco A, Sarullo FM, Lanza GA, Crea F. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol. 2013;112:8-13.
30. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 1998;97:1695-1701.
31. Prior JO, Quinones MJ, Hernandez-Pampaloni M, Facta AD, Schindler TH, Sayre JW, Hsueh WA, Schelbert HR. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation. 2005;111:2291-2298.
32. Lovelock JD, Monasky MM, Jeong EM, Lardin HA, Liu H, Patel BG, Taglieri DM, Gu L, Kumar P, Pokhrel N, Zeng D, Belardinelli L, Sorescu D, Solaro RJ, Dudley SC Jr. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res. 2012;110:841-850.
33. Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, Lang C, Wachter R, Edelmann F, Hasenfuss G, Jacobshagen C. Ranolazine for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail. 2013;1:115-122.
34. Bairey Merz CN, Handberg EM, Shufelt CL, Mehta PK, Minissian MB, Wei J, Thomson LE, Berman DS, Shaw LJ, Petersen JW, Brown GH, Anderson RD, Shuster JJ, Cook-Wiens G, Rogatko A, Pepine CJ. A randomized, placebocontrolled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur Heart J. 2016;37:1504-1513.
35. Sutherland CG, Fisher BM, Frier BM, Dargie HJ, More IA, Lindop GB. Endomyocardial biopsy pathology in insulin-dependent diabetic patients with abnormal ventricular function. Histopathology. 1989;14:593-602.
36. Sunni S, Bishop SP, Kent SP, Geer JC. Diabetic cardiomyopathy. A morphological study of intramyocardial arteries. Arch Pathol Lab Med. 1986;110:375-381.
37. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787-790.
38. Cosentino F, Katusic ZS. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation. 1995;91:139-144.
39. 13N ammonia myocardial imaging at rest and with exercise in normal volunteers. Quantification of absolute myocardial perfusion with dynamic positron emission tomography. Circulation. 1989;80:1328-1337.